Cognizant sees quarterly revenue above estimates on strong enterprise demand
Cognizant's services have seen strong uptake from enterprises looking to automate processes and shift workloads to the cloud as they adopt AI in the hopes of boosting productivity and optimizing costs.
"Our investments in talent, platforms and AI infrastructure drove our fourth-straight quarter of organic year-over-year revenue growth," said Cognizant CEO Ravi Kumar S.
The company forecast third-quarter revenue between $5.27 billion and $5.35 billion, compared with analysts' expectations of $5.27 billion, according to data compiled by LSEG.
It reported revenue of $5.25 billion in the second quarter, beating estimates of $5.19 billion.
Cognizant reported earnings per share of $1.31 in the quarter ended June 30, compared with a profit of $1.14 per share a year ago.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform
HOUSTON and SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced it has received its second U.S. Food and Drug Administration (FDA) 510(k) clearance. The clearance expands the use of its RS001 cardio-respiratory wearable to home environments and includes approval for its connected care platform marketed as 1Bio™. Illustrative Image of Respiree's RS001 Wearable With its Connected Care 1Bio™ Platform The RS001 is a chest-worn device that directly measures respiration and offers passive cardio-respiratory monitoring. Originally cleared for in-patient clinical use, the RS001's use in home settings marks a significant step toward more accessible and preventive healthcare. The device connects to a cellular hub, which enables data to be visualized in real time via the connected care 1Bio™ dashboard. 'Respiration is the most predictive vital sign for clinical deterioration, yet it remains underutilized – particularly outside hospital settings,' said Dr. Gurpreet Singh, CEO and Founder of Respiree. 'This FDA 510(k) extension allows healthcare systems to passively and accurately monitor leading indicators in the home, enabling earlier interventions and reducing the overall burden on healthcare infrastructure.' The announcement follows Respiree's recent US$11.6 million Series A financing round, led by We Venture Capital and ClavystBio, which will accelerate development toward potential regulatory approvals and global market expansion. Respiree also announced plans to pursue additional FDA clearances for its proprietary AI software, aiming to integrate artificial intelligence models into the 1Bio™ platform for both inpatient and home-based care. 'These are exciting times for us,' added Dr. Singh. 'Our first 510(k) was for the wearable; this second one is for the platform. We are now focused on bringing our flagship AI models into the fold as a Software as a Medical Device (SaMD).' About Respiree Respiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare's care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA). ( Media Enquiries Evangeline FuAdministrative ManagerRespiree Pte LtdEmail: evangeline@ A photo accompanying this announcement is available at in to access your portfolio
Yahoo
5 minutes ago
- Yahoo
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00amEST. The event will be webcast live and the registration link can be found here. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit and follow us on Facebook, Instagram, LinkedIn and Twitter/X. CONTACT: Investor Contact: Praxis Precision Medicines investors@ 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@ 617-430-7576Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Lender Itau hikes net interest income outlook as profit edges above forecasts
SAO PAULO (Reuters) -Brazilian lender Itau Unibanco on Tuesday posted a 14.3% rise in second-quarter net recurring profit from a year earlier, slightly beating estimates while also upping its yearly projection for the growth of net interest income with clients. Itau, Latin America's most valuable bank by market value, reported an 11.5 billion reais ($2.09 billion) net recurring profit for the quarter through the end of June, compared to an estimate of 11.3 billion reais from analysts polled by LSEG. The Brazilian lender's annualized return on equity (ROE), a gauge of profitability, stood at 23.3%, rising from 22.4% a year earlier. The lender said it expects the net interest income (NII) with clients to grow between 11% and 14% this year, from 7.5% to 11.5% previously. Itau also revised the effective tax rate to between 28.5% and 30.5% this year, from a range between 27% and 29% previously. In a separate filing, Itau announced interest on equity to shareholders of about 0.36 real per share. ($1 = 5.5043 reais) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
